Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BIVI
BIVI logo

BIVI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy BioVie Inc (BIVI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.760
1 Day change
-1.68%
52 Week Range
12.100
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BioVie Inc (BIVI) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has no recent trading signals, and exhibits a declining price trend. While technical indicators show some bullish signs, the absence of strong financial data, news, or influential trading activity makes it a hold rather than a buy.

Technical Analysis

The MACD histogram is positive at 0.0168, indicating a bullish signal, but it is contracting. RSI is at 65.415, in the neutral zone, suggesting no clear momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Support and resistance levels indicate a pivot at 1.699, with resistance at 1.817 and 1.89, and support at 1.58 and 1.507. However, the recent price trend shows a decline, with the stock down 1.68% in the regular market and 1.23% post-market.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • Bullish moving averages and a positive MACD histogram.

Neutral/Negative Catalysts

  • Declining price trend (-1.68% regular market, -1.23% post-market), no recent news, no significant hedge fund or insider trading activity, no recent congress trading data, and a 60% chance of a negative return over the next month (-11.31%).

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast BIVI stock price to rise
Analyst Rating
0
Wall Street analysts forecast BIVI stock price to rise
Buy
Hold
Sell
0
Current: 1.790
sliders
Low
0
Averages
0
High
0
0
Current: 1.790
sliders
Low
0
Averages
0
High
0
Brookline
NULL -> Buy
maintain
$6 -> $12
AI Analysis
2025-08-29
Reason
Brookline
Price Target
$6 -> $12
AI Analysis
2025-08-29
maintain
NULL -> Buy
Reason
Brookline adjusted the firm's price target on BioVie to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company's recent 1-for-10 reverse stock split for the target adjustment. It believes BioVie's cash position provides a runway through fiscal 2026.

People Also Watch